Valuation: Axonics, Inc.

Market Cap 3.63B 3.14B 2.94B 2.68B 5.06B 346B 5.13B 34.42B 13.51B 173B 13.62B 13.32B 576B P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 3.31B 2.87B 2.68B 2.45B 4.61B 316B 4.69B 31.41B 12.33B 158B 12.43B 12.16B 526B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 2013-09-30
Director of Finance/CFO 41 2023-10-01
Chief Operating Officer 47 2018-07-31
Director TitleAgeSince
Director/Board Member 69 2018-01-31
Director/Board Member 74 2019-04-07
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.10% - - 3.63B
+2.00%+1.35%-8.41%+22.19% 133B
+0.36%-7.64%-17.53%-1.65% 12.57B
+0.78%+6.17%+114.32%+145.69% 10.7B
+0.30%-0.35%-42.48%-67.21% 4.72B
-0.79%+3.51%-24.77%+37.61% 2.68B
-0.73%+14.36%-24.54%-75.80% 1.73B
+0.98%+1.30%-14.30%-12.41% 1.7B
+0.69%-2.02%-33.31%-31.58% 1.67B
Average +0.28%+0.64%-6.38%+2.11% 21.05B
Weighted average by Cap. +1.55%+2.60%-2.99%+24.11%

Financials

2022 2023
Net sales 274M 237M 221M 202M 381M 26.1B 387M 2.6B 1.02B 13.06B 1.03B 1.01B 43.49B 366M 317M 296M 271M 511M 34.94B 519M 3.48B 1.36B 17.48B 1.38B 1.35B 58.22B
Net income -59.7M -51.68M -48.31M -44.15M -83.2M -5.69B -84.5M -566M -222M -2.85B -224M -219M -9.49B -6.09M -5.27M -4.93M -4.5M -8.48M -581M -8.62M -57.77M -22.67M -290M -22.86M -22.36M -967M
Net Debt -348M -301M -282M -257M -485M -33.2B -493M -3.3B -1.3B -16.61B -1.31B -1.28B -55.32B -317M -275M -257M -235M -442M -30.27B -449M -3.01B -1.18B -15.14B -1.19B -1.17B -50.43B
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB